PART1

Summary

PART1 (prostate androgen-regulated transcript 1, HGNC:17263) is a long non-coding RNA gene on chromosome 5q12.1.

This gene is induced by androgen in prostate adenocarcinoma cells. Multiple alternatively transcript variants have been described for this gene, none of which are predicted to encode a protein product.

Source: NCBI Gene 25859 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17263
Approved symbol	PART1
Name	prostate androgen-regulated transcript 1
Location	5q12.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	DKFZP586D0823, NCRNA00206
Ensembl gene	ENSG00000152931
Ensembl biotype	lncRNA
OMIM	604991
Entrez	25859
RNAcentral	URS000075B1B9 — lncRNA, 2495 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 lncRNA

ENST00000504876, ENST00000506884, ENST00000515734, ENST00000661844, ENST00000663388, ENST00000664492, ENST00000667192, ENST00000673670, ENST00000673825, ENST00000674007, ENST00000674024, ENST00000674053, ENST00000814274, ENST00000814275

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000504876 — 2 exons

Exon	Start	End
ENSE00002023508	60488207	60488423
ENSE00002086953	60521020	60526418

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 92.70.

FANTOM5 (CAGE): breadth broad, TPM avg 2.9219 / max 339.7818, expressed in 276 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
56603	2.5758	269
56606	0.2495	41
56604	0.0518	21
56601	0.0231	12
56605	0.0217	10

Top tissues by expression

268 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	92.70	gold quality
middle temporal gyrus	UBERON:0002771	92.56	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.67	gold quality
orbitofrontal cortex	UBERON:0004167	89.36	gold quality
Brodmann (1909) area 46	UBERON:0006483	89.04	gold quality
superior frontal gyrus	UBERON:0002661	87.30	gold quality
Brodmann (1909) area 10	UBERON:0013541	87.28	gold quality
frontal pole	UBERON:0002795	86.61	gold quality
prefrontal cortex	UBERON:0000451	85.83	gold quality
right uterine tube	UBERON:0001302	85.74	gold quality
frontal cortex	UBERON:0001870	84.75	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	83.39	gold quality
postcentral gyrus	UBERON:0002581	83.25	gold quality
neocortex	UBERON:0001950	83.23	gold quality
Brodmann (1909) area 9	UBERON:0013540	83.05	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	82.82	gold quality
right frontal lobe	UBERON:0002810	81.65	gold quality
parietal lobe	UBERON:0001872	81.45	gold quality
cingulate cortex	UBERON:0003027	79.55	gold quality
anterior cingulate cortex	UBERON:0009835	79.48	gold quality
cerebral cortex	UBERON:0000956	79.39	gold quality
prostate gland	UBERON:0002367	79.38	gold quality
descending thoracic aorta	UBERON:0002345	79.19	gold quality
primary visual cortex	UBERON:0002436	78.39	gold quality
popliteal artery	UBERON:0002250	77.89	gold quality
tibial artery	UBERON:0007610	77.85	gold quality
paraflocculus	UBERON:0005351	76.26	gold quality
CA1 field of hippocampus	UBERON:0003881	76.21	gold quality
aorta	UBERON:0000947	76.16	gold quality
occipital lobe	UBERON:0002021	75.87	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.90

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 25)

• Prostrate androgen-regulated transcript-1 (PART-1) was highly expressed in colorectal cancer cells and tissues, and knockdown of PART-1 suppressed cell proliferation and metastasis, both in vitro and in vivo; in addition, PART-1 functioned as a ceRNA of DNMT3A, by sponging miR-143; finally, PART-1 induced tumor progression by regulating DNMT3A (PMID:28619512)
• these data suggest that the knockdown of prostrate androgen-regulated transcript-1 represents a tumor suppressor player in bladder cancer and contributes to the inhibition of tumor proliferation, the promotion of cell apoptosis, and the suppression of cell invasion. Prostrate androgen-regulated transcript-1 may function as a new prognostic biomarker and as a feasible therapeutic target for patients with bladder cancer. (PMID:31311442)
• Long noncoding RNA PART1 promotes progression of non-small cell lung cancer cells via JAK-STAT signaling pathway. (PMID:31436388)
• LncRNA PART-1 targets TGFBR2/Smad3 to regulate cell viability and apoptosis of chondrocytes via acting as miR-590-3p sponge in osteoarthritis. (PMID:31571401)
• LncRNA PART1 modulates chondrocyte proliferation, apoptosis, and extracellular matrix degradation in osteoarthritis via regulating miR-373-3p/SOX4 axis. (PMID:31646607)
• LncRNA PART1 regulates colorectal cancer via targeting miR-150-5p/miR-520h/CTNNB1 and activating Wnt/beta-catenin pathway. (PMID:31669140)
• LncRNA PART1 facilitates the malignant progression of colorectal cancer via miR-150-5p/LRG1 axis. (PMID:31898365)
• PART1 and hsa-miR-429-Mediated SHCBP1 Expression Is an Independent Predictor of Poor Prognosis in Glioma Patients. (PMID:32351983)
• Silencing of lncRNA PART1 inhibits proliferation, invasion and migration of breast cancer cells and promotes the efficacy of cisplatin in breast cancer cells. (PMID:32700682)
• Long noncoding RNA PART1 restrains aggressive gastric cancer through the epigenetic silencing of PDGFB via the PLZF-mediated recruitment of EZH2. (PMID:32901105)
• lncRNA PART1, manipulated by transcriptional factor FOXP2, suppresses proliferation and invasion in ESCC by regulating the miR18a5p/SOX6 signaling axis. (PMID:33432363)
• LncRNA PART1 promotes cell proliferation and inhibits apoptosis of oral squamous cell carcinoma by blocking EZH2 degradation. (PMID:33725092)
• Long non-coding RNA PART1 predicts a poor prognosis and promotes the malignant progression of pancreatic cancer by sponging miR-122. (PMID:33865422)
• YY1-Induced lncRNA PART1 Enhanced Resistance of Ovarian Cancer Cells to Cisplatin by Regulating miR-512-3p/CHRAC1 Axis. (PMID:34030482)
• LncRNA PART1 alleviated myocardial ischemia/reperfusion injury via suppressing miR-503-5p/BIRC5 mediated mitochondrial apoptosis. (PMID:34082009)
• The Role of Tumor-related LncRNA PART1 in Cancer. (PMID:34225608)
• LncRNA PART1/miR-185-5p/RUNX3 feedback loop modulates osteogenic differentiation of bone marrow mesenchymal stem cells. (PMID:34431433)
• PART1 destabilized by NOVA2 regulates blood-brain barrier permeability in endothelial cells via STAU1-mediated mRNA degradation. (PMID:34990795)
• LncRNA PART1 Stimulates the Development of Ovarian Cancer by Up-regulating RACGAP1 and RRM2. (PMID:35553409)
• Long noncoding RNA PART1: dual role in cancer. (PMID:35864416)
• Associations of PART1 and DEFB1 polymorphisms with Dental Caries in twelve-year-old children in Southern China: a cross-sectional study. (PMID:36597064)
• Exosome-mediated long noncoding RNA (lncRNA) PART1 suppresses malignant progression of oral squamous cell carcinoma via miR-17-5p/SOCS6 axis. (PMID:37476905)
• Friend leukemia integration 1 overexpression decreases endometrial receptivity and induces embryo implantation failure by promoting PART1 transcription in the endometrial epithelial cells. (PMID:37780395)
• LncRNA PART1 Regulates Ovarian Carcinoma Development via the miR-150-5p/MYB Axis. (PMID:37919051)
• Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer. (PMID:39181433)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.